Approximately 270-300 million people worldwide are infected with hepatitis C, and about 1%-2% of the U.S. population is infected. This infectious disease can lead to scarring of the liver, cirrhosis, and eventually liver failure. A significant number of infected patients develop liver disease or cancer. The current standard treatment is interferon, which has only a 50% success rate. Compounding the 50% failure rate are severe side effects which lead many people to discontinue treatment.

Dr. Samuel Wheeler French Jr., MD, PhD, Assistant Professor of Pathology and Laboratory Medicine at UCLA and researcher at UCLA''s Jonsson Comprehensive Cancer Center, is a liver pathologist who is currently developing a proteomic-based program to study the development of liver cancer from hepatitis C viral infection. His most recent study results, to be presented in an American Society for Investigative Pathology (ASIP) symposium on "Pathobiology of Liver Injury and Fibrosis" on Tuesday afternoon, April 12 at Experimental Biology 2011, evaluate the effects of several flavonoids on hepatitis C viral infection. Previously, Dr. French has shown that quercetin, a plant-derived bioflavonoid used by some as a nutritional supplement, attenuates Hepatitis C virus production with no cell toxicity. In his most recent research, French and colleagues found that two other bioflavonoids, catechin and naringenin, displayed antiviral activity on tissue culture. The next step is to determine through a Phase I Clinical Trial that they are safe for patients with chronic hepatitis C infection.


Read more: New Compounds Could Further Treatment Options Against Hepatitis C Infection http://www.medindia.net/news/New-Compounds-Could-Further-Treatment-Options-Against-Hepatitis-C-Infection-83600-1.htm#ixzz1JUKlechm